Loading stock data…
Mineralys Therapeutics (MLYS)
$29.79+1.58 (+5.58%)
Market OpenUpdated 10:05 AM EDT
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Mineralys Therapeutics, Inc. in the Healthcare sector is trading at $31.12 with a market capitalization of $2.1B. Wall Street consensus targets $48.50 (8 analysts), implying a +55.8% move over the next 12 months. The stock is currently 35% below its 52-week high of $47.65, remaining 5.3% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +55.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$45.34M↓ | -$38.28M↑ | -$41.13M↑ | -$46.75M↓ | -$44.45M |
| Net Income | -$39.34M↓ | -$32.23M↑ | -$36.93M↑ | -$43.27M↓ | -$42.21M |
Peer Comparison
JNJUNHPFE
Fundamentals
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.08B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-23.78%
Volume
Today's trading volume
193,455
Recent News
Mineralys (MLYS) Q2 2026 Earnings Call Transcript
Lorundrostat advances toward December FDA decision as company ramps commercial launch.
Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ...
Mineralys Therapeutics Inc (MLYS) reports positive clinical results and robust funding, but faces significant Q2 net loss and competitive pressures ahead of PDUFA date.
Mineralys Therapeutics, Inc. Q2 2026 Earnings Call Summary
Moby summary of Mineralys Therapeutics, Inc.'s Q2 2026 earnings call
Mineralys Therapeutics Q2 Earnings Call Highlights
Mineralys Therapeutics (NASDAQ:MLYS) said it is continuing commercial-launch preparations for lorundrostat ahead of its December 22 Prescription Drug User Fee Act target date, while reporting a wider second-quarter loss driven largely by a $200 million upfront payment related to its amended agreemen
Mineralys Therapeutics (MLYS) Heads Into Earnings As Lorundrostat Hopes Meet Undervalued View
Mineralys Therapeutics (MLYS) plans to report its second quarter 2026 results on August 11, 2026, accompanied by a conference call and webcast that could clarify how investors view the stock’s recent performance. See our latest analysis for Mineralys Therapeutics. Mineralys Therapeutics’ share price has pulled back recently, with a 30 day share price return of a 4.3% decline and a year to date share price return of a 25.8% decline. However, the 1 year total shareholder return sits at 97.6%...